pricniple of accounting

7/30/2019 pricniple of accounting

1/9

FINANCIALACCOUNTING 2010

Submitted To Miss Moona

GLAXO SMITH KLINE


2/9

GSK

PRINCIPLES OF ACCOUNTING


3/9

GSK


NAMES OF GROUP MEMBE


4/9

GSK


GlaxoSmithKline plc (GSK) is a global healthcare company engaged in thedevelopment, manufacturing and marketing of pharmaceutical and consumer healthrelated products.

Its products are targeted towards three diseases namely HIV/AIDS, tuberculosis andmalaria. The company principally operates through two segments, namelyPharmaceuticals and Consumer Healthcare. The Pharmaceutical segment includesprescription pharmaceuticals and vaccines; and the Consumer Healthcare segmentprovides over-the-counter medicines, oral care and nutritional healthcare products.Its operations are concentrated in United States, France, Japan, United Kingdom,Italy, Germany and Spain.

The company principally operates through two segments, namely Pharmaceuticals

and Consumer Healthcare. The Pharmaceutical segment includes prescription

pharmaceuticals and vaccines; and the Consumer Healthcare segment provides over-

the-counter medicines, oral care and nutritional healthcare products. Its operationsare concentrated in United States, France, Japan, United Kingdom, Italy, Germany

and Spain.


5/9

GSK


GSK Pakistan Limited was created on January 1st 2000 through the merger ofSmithKline Beecham (Pakistan) and Glaxo Wellcome (Pakistan) and it stands as thelargest pharmaceutical company in Pakistan today.

GSK leads the industry in value, volume and prescription market shares. We areproud of our consistency and stability in sales, profits and growth.

Some of our key brands include Augmentin, Panadol, Seretide, Betnovate, Zantacand Calpol in medicine and renowned consumer healthcare brands include Horlicks,Aquafresh, Macleans and ENO.

GSK dedicated to R&D for 80 years Cost of bringing a medicine to market: $800 million (Rs 4.8 billion) Average length of time to discover new drug: 10-15 years 5 out of every 10,000 compounds investigated reach clinical trial phase and only 1 of

those gets approved for patient use.

GSK has industry's most extensive portfolio of R&D projects for diseases affecting

developing countries .The report provides a comprehensive insight into the


6/9

GSK


company, including business structure and operations, executive biographies and key

competitors.

Provides key company information for business intelligence needs.

The companys strengths and weaknesses and areas of development or

decline are analyzed. Financial, strategic and operational factors areconsidered.

The opportunities open to the company are considered and its growthpotential assessed. Competitive or technological threats are highlighted.

The report contains critical company information business structure andoperations, the company history, major products and services, keycompetitors, key employees and executive biographies, different locations andimportant subsidiaries.

The report provides detailed financial ratios for the past five years as well as

interim ratios for the last four quarters.

Financial ratios include profitability, margins and returns, liquidity andleverage, financial position and efficiency ratios.


7/9

GSK


ACKNOWLEDGMENT:

Firstly, we thank Allah for us the strength and ability to complete this term report.

We express our gratitude to all those who gave us the possibility to complete this

term report by providing us the information about the GSK finance information.

Which helped us in formulating this report and guided us through out. We want to

thank our teacher which gave us the opportunity to commence this term report in

the first instance, to do the necessary research work and to use locals data. We are

bound to thank honorable Miss: Moona Shamim whose guidance was always with us

whenever we need it. We are deeply indebted to companys profile for their

stimulating suggestions and encouragement helped us in all the time of research and

for writing of this term report. We want to thank our teacher for her help, support,

interest and valuable hints.


8/9

GSK


The top competitors of GSK are PIFIZER INC, NOVARTIS AG, PHARMA and SANOFIAVENTIS. These are the tough competitors of GSK in todays market. GSK has to providebetter drugs if they want to attract their customers towards it. Britains state-run health service

will get a partial rebate from GlaxoSmithKline, if their drug is not better than Pfizers.


9/9

GSK


After all observations and calculations we concluded that:

In activity turnover: Debtor Turnover Ratio shows 13% change in 2008 from 2009,

Fixed Asset Turn Over shows -39.28% negative change and Working Capital shows apositive change of 486%.

Where as in profitability ratios: Gross Profit show change of -20.54% which isnegative change. Current Ratio shows negative change of -17.6%

In 2009 Net Income was 8,932,000 and in 2008Net Income was6,822,505.Its means

that 2009 is much more profitable as compare to 2008.

The two organizations Glaxo Wellcome and SmithKline merge together; this is where

two big successful organisations come together, not to protect future earnings

growth but actually to increase critical mass to really out perform the industry. Themore effort, the more money, and the more power you can put to research, the

stronger the company is going to be.

pricniple of accounting

Documents